ALKS: Q2 2026 revenue and profitability surged following the Avadel acquisition and product growthQuartr·2 days ago, 06:47 AMALKS+3.84%AVDL0.00%
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2MTradingView·2 days ago, 06:13 AMALKS+3.84%AVDL0.00%
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition NearsMarket Beat·Jun 10 at 01:08 PMALKS+3.84%AVDL0.00%
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD CowenMarket Beat·Mar 2 at 09:02 PMALKS+3.84%VHT-1.32%
Alkermes plc Announces CEO Succession Plan | ALKS Stock NewsStockTitan·Feb 24 at 09:55 PMALKS+3.84%XBI+2.45%
REG - Goldman Sachs & Co. Avadel Pharma plc - Form 38.5b - Avadel Pharmaceuticals PLCLondon Stock Exchange·Feb 13 at 08:34 AMGS-C-0.21%XLF+0.58%
REG - BlackRock Group Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plcLondon Stock Exchange·Feb 12 at 09:20 AMAVDL0.00%BLK+1.83%
REG - Rubric Capital Mgmt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plcLondon Stock Exchange·Feb 12 at 08:25 AMAVDL0.00%
RFG Advisory LLC Acquires New Holdings in Avadel Pharmaceuticals PLC. $AVDLMarket Beat·Feb 12 at 05:38 AMAVDL0.00%
REG - Morgan Stanley&CoLLC Avadel Pharma plc - Rule 38.5_A - Avadel Pharmaceuticals plcLondon Stock Exchange·Feb 12 at 02:12 AMAVDL0.00%
REG - JP Morgan Sec LLC Avadel Pharma plc - Form 38.5b (EPT/NON-RI)-Avadel Pharmaceuticals plcLondon Stock Exchange·Feb 11 at 04:53 AMXLF+0.58%VFH+0.53%
REG - Morgan Stanley Cap Avadel Pharma plc - RULE 38.5_A - Avadel Pharmaceuticals plcLondon Stock Exchange·Feb 11 at 01:48 AMPHEQ+0.68%MSSM+1.01%
